Identifying and Developing Breakthrough Medicines

Bexion Pharmaceuticals is a mid-stage clinical company developing life-changing treatments in Oncology and CNS.

The company’s lead compound, BXQ-350, is a novel S1P modulator. With our highly experienced biotech leadership team and expertise in Oncology, we are urgently progressing our pipeline to develop life-changing oncology therapies on our path to becoming a leading biotech/pharmaceutical company.


Learn more about Bexion Pharmaceuticals through our highlights video


Dr. Richard Curry, III Medical Director at CTI and Medical Affairs Advisory at Bexion Pharmaceuticals, Inc. recently presented at the 3rd Annual Glioblastoma Drug Development Summit.


Bexion Pharmaceuticals Corporate Video

Upcoming Events